Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$39.5M | -$52.0M | -$3.65M | -$21.0M | -$14.9M | -$21.4M | -$41.7M | -$43.0M | -$36.3M | -$31.5M |
| Net income | -$38.8M | -$50.9M | -$3.84M | -$7.00M | -$14.8M | -$16.9M | -$40.9M | -$42.9M | -$37.6M | -$34.5M |
| EPS (diluted) | — | — | $1.15 | -$1.44 | -$0.89 | -$0.66 | -$1.43 | -$1.39 | -$1.03 | -$0.74 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.2M | -$40.7M | -$1.57M | -$18.1M | -$13.1M | -$12.5M | -$25.7M | -$33.6M | -$35.0M | -$27.8M |
| Capital expenditures | $687K | $189K | $0.00 | — | — | — | — | $0.00 | $29.0K | $0.00 |
| Free cash flow | -$32.9M | -$40.9M | -$1.57M | — | — | — | — | -$33.6M | -$35.1M | -$27.8M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $106M | $88.1M | $104K | $12.2M | $28.8M | $65.2M | $73.8M | $56.6M | $41.7M | $26.7M |
| Total assets | $111M | $92.6M | $164K | $14.5M | $30.9M | $67.2M | $77.0M | $59.4M | $45.4M | $30.5M |
| Total liabilities | — | — | $2.23M | $2.79M | $3.76M | $3.99M | $33.0M | $33.3M | $26.4M | $21.2M |
| Shareholders' equity | $89.3M | -$610K | -$2.07M | $11.7M | $27.1M | $63.2M | $44.0M | $26.1M | $37.2M | $22.4M |
| Retained earnings | -$101M | -$152M | -$21.9M | -$28.9M | -$43.8M | -$60.7M | -$102M | -$145M | -$182M | -$217M |
| Shares (wtd avg diluted) | 28.9M | 30.9M | 3.42M | 5.28M | 16.7M | 25.6M | 28.6M | 31.0M | 36.5M | 46.4M |
Every figure is extracted from PDS Biotechnology Corp’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.